INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Lawver Teri L reported CLDX

SVP & Chief Commercial Officer · Celldex Therapeutics, Inc. · Celldex Therapeutics, Inc. — ISO (right to buy)

Side
A
Value
—
Shares
100.0K
Price
—
Executed
Nov 10, 2025
Disclosed
Nov 12, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 10 executedNov 12, 2025 disclosed

CLDX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CLDX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JR
    Jain RitaDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LSVP & Chief Commercial Officer
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    90.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    93.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    TD
    Torres DeniceDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HM
    Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    95.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CS
    Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    95.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MB
    Martin Samuel BatesSVP AND CFO
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    93.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CE
    Crowley ElizabethSR. VP & CPDO
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    28
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Open-market sale
    		SELL$121K
    4,166 sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001960596-25-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 10, 2025
    Published
    Nov 12, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Lawver Teri L
    Role
    SVP & Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Celldex Therapeutics, Inc. — ISO (right to buy)
    Ticker
    CLDX
    Shares
    100.0K
    Price per share
    $0
    Execution date (reported)
    Nov 10, 2025
    Owned after transaction
    100.0K shares
    Days from execution to publication
    2

    What this establishes

    Lawver Teri L filed this Form 4 reporting a grant or award of CLDX on Nov 10, 2025. It became public on Nov 12, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP & Chief Commercial Officer
    Lawver Teri Lcik:0001960596
    Issuer
    Celldex Therapeutics, Inc.cik:0000744218

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.